A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ.

Schnapp, Aviad; Harel, Moria; Cayam-Rand, Dalit; Cassuto, Hanoch; Polyansky, Lola; Aran, Adi

Schnapp, Aviad; Harel, Moria; Cayam-Rand, Dalit; Cassuto, Hanoch; Polyansky, Lola; Aran, Adi.

Afiliação

Schnapp A; Department of Pediatrics, Hadassah Medical Center, Jerusalem 91120, Israel.
Harel M; Neuropediatric Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Cayam-Rand D; Neuropediatric Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Cassuto H; Child Development Centers, Leumit Health Services, Jerusalem 9439221, Israel.
Polyansky L; Neuropediatric Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Aran A; Neuropediatric Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.

Biomedicines ; 10(7)2022 Jul 13.

Article em En | MEDLINE | ID: mdl-35884990

Palavras-chave

autism spectrum disorder; cannabidiol; cannabinoids; child psychiatry; clinical trials; developmental disorders; randomized controlled; sleep; tetrahydrocannabinol

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article